Syncom Formulations (India) Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Syncom Formulations (India) yıllık ortalama 9.4% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 13.4% annual. Gelirler growing yılda ortalama 4.5% oranında artmaktadır. Syncom Formulations (India)'in özkaynak karlılığı 9.9% ve net marjı 9.8%'dir.

Anahtar bilgiler

9.4%

Kazanç büyüme oranı

8.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	17.5%
Gelir büyüme oranı	4.5%
Özkaynak getirisi	9.9%
Net Marj	9.8%
Sonraki Kazanç Güncellemesi	11 Nov 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Syncom Formulations (India) nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BSE:524470 Gelir, gider ve kazançlar (INR Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	2,908	286	371
31 Mar 24	2,634	253	379
31 Dec 23	2,498	264	365
30 Sep 23	2,420	235	340
30 Jun 23	2,327	206	285
31 Mar 23	2,243	201	288
31 Dec 22	2,215	164	263
30 Sep 22	2,213	162	250
30 Jun 22	2,198	183	222
31 Mar 22	2,197	198	237
31 Dec 21	2,270	220	240
30 Sep 21	2,539	280	230
30 Jun 21	2,668	316	212
31 Mar 21	2,448	292	206
31 Dec 20	2,223	257	182
30 Sep 20	1,905	192	171
30 Jun 20	1,809	143	158
31 Mar 20	2,055	143	177
31 Dec 19	2,237	130	181
30 Sep 19	2,191	133	181
30 Jun 19	2,077	120	159
31 Mar 19	1,868	111	174
31 Dec 18	1,648	106	173
30 Sep 18	1,566	97	171
30 Jun 18	1,505	87	151
31 Mar 18	1,586	86	171
31 Mar 17	1,848	105	164
31 Mar 16	1,839	104	149
31 Mar 15	1,734	98	168
31 Mar 14	1,513	93	299
31 Dec 13	1,429	78	254

Kaliteli Kazançlar: 524470 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 524470 'nin mevcut net kar marjları (9.8%) geçen yılın (8.9%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 524470 şirketinin kazancı son 5 yılda yılda 9.4% oranında arttı.

Büyüme Hızlandırma: 524470 'un son bir yıldaki kazanç büyümesi ( 38.6% ) 5 yıllık ortalamasını (yıllık 9.4% ) aşıyor.

Kazançlar vs. Sektör: 524470 geçen yılki kazanç büyümesi ( 38.6% ) Pharmaceuticals sektörünün 19.1% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 524470 'nin Özsermaye Getirisi ( 9.9% ) düşük olarak değerlendiriliyor.

Syncom Formulations (India) Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024

First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)

Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024

Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)

Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)

Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)

Recent updates

Syncom Formulations (India) Limited to Report Q2, 2025 Results on Nov 11, 2024

Investor sentiment deteriorates as stock falls 15%

Investor sentiment improves as stock rises 22%

Syncom Formulations (India) Limited, Annual General Meeting, Sep 30, 2024

First quarter 2025 earnings released: EPS: ₹0.11 (vs ₹0.07 in 1Q 2024)

Syncom Formulations (India) Limited to Report Q1, 2025 Results on Aug 12, 2024

Investor sentiment improves as stock rises 17%

Full year 2024 earnings released: EPS: ₹0.34 (vs ₹0.22 in FY 2023)

Investor sentiment improves as stock rises 17%

Syncom Formulations (India) Limited Announces Board Changes

Third quarter 2024 earnings released: EPS: ₹0.09 (vs ₹0.06 in 3Q 2023)

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 25%

Second quarter 2024 earnings released: EPS: ₹0.08 (vs ₹0.06 in 2Q 2023)

Investor sentiment improves as stock rises 23%

Syncom Formulations (India) Limited to Report Q3, 2024 Results on Feb 14, 2024

Syncom Formulations (India) Limited, Annual General Meeting, Sep 26, 2023

First quarter 2024 earnings released

Investor sentiment improves as stock rises 18%

Syncom Formulations (India) Limited to Report Q1, 2024 Results on Aug 14, 2023

Full year 2023 earnings released: EPS: ₹0.24 (vs ₹0.24 in FY 2022)

Investor sentiment deteriorates as stock falls 18%

Third quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.07 in 3Q 2022)

Syncom Formulations (India) Limited to Report Q3, 2023 Results on Feb 13, 2023

Investor sentiment improved over the past week

Second quarter 2023 earnings released: EPS: ₹0.06 (vs ₹0.06 in 2Q 2022)

Insufficient new directors

Syncom Formulations (India) Limited Approves the Declaration of Dividend for the Financial Year Ended 31 March 2022

Upcoming dividend of ₹0.03 per share

First quarter 2023 earnings released: EPS: ₹0.03 (vs ₹0.08 in 1Q 2022)

Syncom Formulations (India) Limited, Annual General Meeting, Sep 19, 2022

Investor sentiment improved over the past week

Syncom Formulations (India) Limited Appoints Ruchi Jindal as an Additional Director

Now 25% undervalued after recent price drop

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: ₹0.26 (vs ₹0.38 in FY 2021)

Investor sentiment deteriorated over the past week

Insufficient new directors

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS ₹0.38 (vs ₹0.17 in FY 2020)

Investor sentiment improved over the past week

New 90-day low: ₹3.09

Third quarter 2021 earnings released: EPS ₹0.13 (vs ₹0.04 in 3Q 2020)

Syncom Formulations (India) Limited to Report Q3, 2021 Results on Feb 12, 2021

New 90-day high: ₹3.72

Syncom Formulations (India) Limited announced that it expects to receive INR 100.787496 million in funding

Market bids up stock over the past week

New 90-day high: ₹1.93

Market bids up stock over the past week

New 90-day low: ₹1.42

First quarter earnings released

Syncom Formulations (India) Limited to Report Q4, 2020 Results on Jun 30, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin